Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Iovance Biotherapeutics (IOVA) Operating Income (2016 - 2025)

Historic Operating Income for Iovance Biotherapeutics (IOVA) over the last 12 years, with Q3 2025 value amounting to -$94.9 million.

  • Iovance Biotherapeutics' Operating Income fell 655.13% to -$94.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$416.5 million, marking a year-over-year increase of 313.66%. This contributed to the annual value of -$395.3 million for FY2024, which is 1417.43% up from last year.
  • As of Q3 2025, Iovance Biotherapeutics' Operating Income stood at -$94.9 million, which was down 655.13% from -$113.8 million recorded in Q2 2025.
  • In the past 5 years, Iovance Biotherapeutics' Operating Income ranged from a high of -$86.6 million in Q4 2024 and a low of -$121.3 million during Q4 2023
  • In the last 3 years, Iovance Biotherapeutics' Operating Income had a median value of -$110.9 million in 2023 and averaged -$107.8 million.
  • Its Operating Income has fluctuated over the past 5 years, first surged by 2860.06% in 2024, then tumbled by 1163.73% in 2025.
  • Quarter analysis of 3 years shows Iovance Biotherapeutics' Operating Income stood at -$121.3 million in 2023, then grew by 28.6% to -$86.6 million in 2024, then dropped by 9.62% to -$94.9 million in 2025.
  • Its Operating Income was -$94.9 million in Q3 2025, compared to -$113.8 million in Q2 2025 and -$121.2 million in Q1 2025.